Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

- Chemotherapy-induced Neutropenia
- Completed

Study Title: Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003)

Teva Identifier: NEUGR-003

ClinicalTrials.gov Identifier: NCT01126190

Study Status: Completed

Trial Condition(s): Chemotherapy-induced Neutropenia

Interventions: Biological: Neugranin | Biological: Pegfilgrastim | Drug: Chemotherapy

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years and older

Trial Duration: 06/01/2010 - 02/01/2012

Phase: Phase 3

Study Type

Interventional